

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

(1) COMPLETION OF ISSUE OF CONVERTIBLE BONDS UNDER SPECIFIC MANDATE; AND (2) ADJUSTMENT RELATING TO THE OUTSTANDING 2024 CONVERTIBLE BONDS

References are made to the circular (the “**Circular**”) of China Biotech Services Holdings Limited (the “**Company**”) dated 22 January 2026, in relation to, among others, the proposed issue of the Convertible Bond under the Specific Mandate. Unless otherwise indicated in this announcement, capitalised terms used herein have the same meanings as those defined in the Circular.

COMPLETION OF ISSUE OF CONVERTIBLE BONDS UNDER SPECIFIC MANDATE

The Board is pleased to announce that all the conditions precedent set out in the Subscription Agreement have been fulfilled and completion of the issue of the Convertible Bonds in the aggregate principal amount of USD35 million to the Subscriber took place on 20 February 2026 in accordance with the terms and conditions of the Subscription Agreement.

EFFECT ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structure of the Company (i) as at the date of this announcement; and (ii) immediately upon full conversion of the Convertible Bonds at the Conversion Price are as follows:

	(i) As at the date of this announcement		(ii) Immediately upon full conversion of the Convertible Bonds at the Conversion Price	
	<i>No. of Shares</i>	<i>Approximate %</i>	<i>No. of Shares</i>	<i>Approximate %</i>
Subscriber	–	–	412,575,757	29.72
Mr. Liu (<i>Note</i>)	1,092,000	0.11	1,092,000	0.08
Genius Lead (<i>Note</i>)	529,500,546	54.27	529,500,546	38.14
Other public Shareholders	445,138,604	45.62	445,138,604	32.06
Total	975,731,150	100.00	1,388,306,907	100.00

Note:

Genius Lead is the registered and beneficial owner of 529,500,546 Shares and Genius Lead is wholly-owned by Genius Earn Limited, which is in turn wholly-owned by Mr. Liu, an executive Director and chairman of the Board. Mr. Liu is the registered and beneficial owner of 1,092,000 Shares and is deemed by virtue of the SFO to be interested in the 529,500,546 Shares held by Genius Lead.

ADJUSTMENT RELATING TO THE OUTSTANDING 2024 CONVERTIBLE BONDS

Prior to completion of the issue of the Convertible Bonds, there were outstanding 2024 Convertible Bonds in the principal amount of US\$6,000,000, which are convertible into a total of 39,250,000 Shares at the conversion price of HK\$1.20 per Share.

As a result of completion of the issue of the Convertible Bonds and in accordance with the terms and conditions of the 2024 Convertible Bonds took place on 20 February 2026, the conversion price of the 2024 Convertible Bonds is adjusted from HK\$1.20 per Share to HK\$1.11 per Share and the maximum number of Shares to be issued by the Company upon conversion of the 2024 Convertible Bonds in full is 42,432,432 Shares, with effect from 20 February 2026, being the date of completion of the issue of the Convertible Bonds. Save for such adjustment, all other terms of the 2024 Convertible Bonds remain unchanged.

Merdeka Corporate Finance Limited, the independent financial adviser of the Company, has certified that the above adjustments to the 2024 Convertible Bonds were made in accordance with the terms of the 2024 Convertible Bonds.

By order of the Board
China Biotech Services Holdings Limited
Chairman and executive Director
Liu Xiaolin

Hong Kong, 20 February 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.